1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Inherent Biosciences

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2019

Location

Salt Lake City UT US

Primary Industry

Biotechnology

About

Based in Utah, US, and founded in 2019 by Andy Olson (CEO), and Kristin Brogaard (CSO), Inherent Biosciences is a diagnostics and therapeutics company that offers epigenetic medicine for complex diseases such as gene dysregulation. In September 2022, Inherent Biosciences raised an undisclosed amount of Series A funding led by Propel Bio Partners, with participation from the Alliance of Angels and Portfolia. The firm uses its epigenetic platform to detect dysregulation across multiple genes and related pathways to diagnose in early stages and treat diseases like infertility, autoimmune disease, autism, and other complex diseases. The company offers products that help patients suffering from infertility, detect prostate cancer, predict embryo quality, and the need for IVF. The company intends to use the September 2022 funding to expand its pipeline, scale commercial operations and generate the further seminal data necessary to add SpermQT to the standard of care.
Current Investors
Alliance of Angels, Portfolia, Propel Bio Partners

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories
Website
www.inherentbio.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.